



Docket: 55 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bowdish et al.

Serial No.: 10/006,591 Filed: December 05, 2001

Examiner: Unassigned Group: Unassigned

For: Engineered Plasmids and Their Use For In Situ Productions
of Genes

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's duty of disclosure under 37 CFR §1.56, Applicant's submit the enclosed references for the Examiner's consideration.

It is respectfully requested that the references submitted with Form PTO-1449 be considered during Examination of the above-identified application and made of record therein. A copy of the references are enclosed. This submission is believed to be in compliance with 37 CFR §1.97 and 1.98.

The citation of the listed items is not a representation that they constitute a complete or exhaustive listing of prior art or that they constitute prior art. The items listed are submitted in good faith, but are not intended to substitute for the Examiner's search. It is hoped, however, that in addition to apprising the Examiner of these particular items, they will assist the Examiner in identifying fields of search and in making as full and complete a search as possible.

The filing of this information disclosure statement is not an admission that the information cited herein is, or is

considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

☐ This information disclosure statement is being filed within three (3) months of the filing date of this application.

☐ This information disclosure statement is being filed within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application.

☐ To the best of Applicant(s) knowledge, this information disclosure statement is being filed before the date of mailing of a first Office Action in connection with this case.

☐ Enclosed herewith is a certificate under 37 C.F.R. § 1.97 (e)(i).

☐ Enclosed herewith is a petition under 37 C.F.R. § 1.97 (d)

☐ Enclosed by check is the petition fee of \$130.00. 37 C.F.R. §1.17 (i)(1).

☐ Please charge the \$130.00 petition fee to Deposit Account No. 01-0483.

☐ Enclosed by check is the \$200.00 fee required by 37 C.F.R. § 1.17 (p).

☐ As set forth in 37 C.F.R. §1.97 (c), to the best of Applicant(s) knowledge, this information disclosure statement is being filed before either the mailing of a final action under §1.113 or the mailing of a notice of allowance under §1.113, and is accompanied by the \$200.00 fee as provided for in 37 C.F.R. §1.17(p).

☐ Please charge the \$200.00 fee required by 37 C.F.R. § 1.17(p) to Deposit Account No. 01-0483.

☒ Please charge any deficiency as well as any other fee(s) which may become due under 37 C.F.R. § 1.16

and/or 1.17 at any time during the pendency of this application, or credit any overpayment of such fee(s) to Deposit Account 01-0483. Also, in the event any extensions of time for responding are required for the pending application(s), please treat this paper as a petition to extend time as required and charge Deposit Account No. 01-0483 therefore. **TWO (2) COPIES OF THIS SHEET ARE ENCLOSED.**

The claims of the application as now presented are believed to patentably distinguish over the prior art and to be in condition for allowance. Early and favorable consideration of the case is respectfully requested.

Respectfully submitted,

Dated: August 11, 2003

Mark Farber

Mark Farber

Registration No. 34,159

Attorney for the Applicants

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410



Image

Docket No.55

1636

1731

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bowdish et al.
Application No: 10/006,591
Filing Date: December 5, 2001 Group Art: Unassigned
For: Engineered Plasmids and Their Use For Situ Productions
Of Genes


CERTIFICATE OF MAILING

Date of Deposit: August 15, 2003

I hereby certify that the following:

- ☒ This Certificate of Mailing
- ☒ Supplemental Information Disclosure Statement
- ☒ PTO Form 1449 and Cited References
- ☒ Return Postcard

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Lori Rooney

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPI considered. Include copy of this form with next communication to applicant.